FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282541331> ?p ?o ?g. }

• W4282541331 endingPage "2974" @default.
• W4282541331 startingPage "2963" @default.
• W4282541331 abstract "Off-label uses of biologics in the treatment of psoriasis are usually implemented in limited-resource settings and studies regarding their response profiles are limited.This was a retrospective study performed in moderate-to-severe plaque-type psoriasis patients who had been treated with either secukinumab, ixekizumab or brodalumab at a university hospital in Thailand between 1 January 2017 and 1 April 2021.A total of 142 patients were included in the data analysis consisting of three groups of 48 patients, 86 patients, and 8 patients treated by secukinumab, ixekizumab, and brodalumab, respectively. Patients were then classified into five groups according to the dosing pattern they received; on-label, off-label with induction, off-label with specific pattern, off-label with irregular dosing interval <8 weeks and >8 weeks. Considering both secukinumab and ixekizumab, the adjusted hazard ratios (95%CI) for complete skin clearance of the four off-label regimens were 2.2(0.9-5.2), 1.9 (0.9-3.9), 1.0 (0.4-2.2), and 1.6 (0.7-3.6), compared to on-label regimen, respectively. In each biologic drug, almost all off-label dosing regimens demonstrated higher adjusted hazard ratios compared to on-label regimen.Off-label, patient-oriented regimens could be a promising choice of IL-17 inhibitors for administration in special settings. Off-label regimens are not inferior in terms of skin clearance to an on-label regimen in the efficacy of psoriasis treatment of secukinumab and ixekizumab but do cause more flares. The decision to use off-label regimens must account for the benefits and associated risks." @default.
• W4282541331 created "2022-06-14" @default.
• W4282541331 creator A5005779747 @default.
• W4282541331 creator A5008555043 @default.
• W4282541331 creator A5022733976 @default.
• W4282541331 creator A5033930205 @default.
• W4282541331 creator A5053177570 @default.
• W4282541331 date "2022-06-23" @default.
• W4282541331 modified "2023-09-24" @default.
• W4282541331 title "On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study" @default.
• W4282541331 cites W1973354423 @default.
• W4282541331 cites W2004348255 @default.
• W4282541331 cites W2007557258 @default.
• W4282541331 cites W2011059902 @default.
• W4282541331 cites W2040391822 @default.
• W4282541331 cites W2136517791 @default.
• W4282541331 cites W2587305350 @default.
• W4282541331 cites W2595206558 @default.
• W4282541331 cites W2609891954 @default.
• W4282541331 cites W2613244920 @default.
• W4282541331 cites W2701201582 @default.
• W4282541331 cites W2735822954 @default.
• W4282541331 cites W2756224147 @default.
• W4282541331 cites W2764109025 @default.
• W4282541331 cites W2768517818 @default.
• W4282541331 cites W2781921947 @default.
• W4282541331 cites W2792924793 @default.
• W4282541331 cites W2883925086 @default.
• W4282541331 cites W2887422108 @default.
• W4282541331 cites W2895932838 @default.
• W4282541331 cites W2897773519 @default.
• W4282541331 cites W2902932442 @default.
• W4282541331 cites W2912436760 @default.
• W4282541331 cites W2920982836 @default.
• W4282541331 cites W2921458915 @default.
• W4282541331 cites W2945527657 @default.
• W4282541331 cites W2947081100 @default.
• W4282541331 cites W2959714341 @default.
• W4282541331 cites W2967437723 @default.
• W4282541331 cites W2969599003 @default.
• W4282541331 cites W2974793973 @default.
• W4282541331 cites W2976146367 @default.
• W4282541331 cites W2988575006 @default.
• W4282541331 cites W2998319702 @default.
• W4282541331 cites W3000356398 @default.
• W4282541331 cites W3004526292 @default.
• W4282541331 cites W3011866593 @default.
• W4282541331 cites W3012480276 @default.
• W4282541331 cites W3015565870 @default.
• W4282541331 cites W3016274701 @default.
• W4282541331 cites W3025504451 @default.
• W4282541331 cites W3035233083 @default.
• W4282541331 cites W3036523869 @default.
• W4282541331 cites W3041170273 @default.
• W4282541331 cites W3041193795 @default.
• W4282541331 cites W3045278545 @default.
• W4282541331 cites W3049405451 @default.
• W4282541331 cites W3089931729 @default.
• W4282541331 cites W3093717103 @default.
• W4282541331 cites W3104634441 @default.
• W4282541331 cites W3106654058 @default.
• W4282541331 cites W3117839071 @default.
• W4282541331 cites W3123517269 @default.
• W4282541331 cites W3157617537 @default.
• W4282541331 cites W3179952304 @default.
• W4282541331 cites W3181850816 @default.
• W4282541331 cites W3185901096 @default.
• W4282541331 cites W3196509200 @default.
• W4282541331 cites W3206208593 @default.
• W4282541331 cites W3211411251 @default.
• W4282541331 cites W3217649772 @default.
• W4282541331 cites W4205472945 @default.
• W4282541331 cites W4205485843 @default.
• W4282541331 cites W4205707695 @default.
• W4282541331 cites W4207013993 @default.
• W4282541331 cites W4210895170 @default.
• W4282541331 cites W4249995199 @default.
• W4282541331 cites W4250753642 @default.
• W4282541331 doi "https://doi.org/10.1080/09546634.2022.2089328" @default.
• W4282541331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35695280" @default.
• W4282541331 hasPublicationYear "2022" @default.
• W4282541331 type Work @default.
• W4282541331 citedByCount "1" @default.
• W4282541331 countsByYear W42825413312023 @default.
• W4282541331 crossrefType "journal-article" @default.
• W4282541331 hasAuthorship W4282541331A5005779747 @default.
• W4282541331 hasAuthorship W4282541331A5008555043 @default.
• W4282541331 hasAuthorship W4282541331A5022733976 @default.
• W4282541331 hasAuthorship W4282541331A5033930205 @default.
• W4282541331 hasAuthorship W4282541331A5053177570 @default.
• W4282541331 hasConcept C126322002 @default.
• W4282541331 hasConcept C16005928 @default.
• W4282541331 hasConcept C207103383 @default.
• W4282541331 hasConcept C2776260265 @default.
• W4282541331 hasConcept C2777288759 @default.
• W4282541331 hasConcept C2779745271 @default.
• W4282541331 hasConcept C2779786854 @default.
• W4282541331 hasConcept C2780564577 @default.

• next